CD19: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It’s the GeneMedi’s summary page for Target/Biomarker Introduction of CD19. The page also collects GeneMedi’s different modalities and formats products for CD19 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the CD19 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Target ID

GM-T56365

Target Name

CD19

Gene ID

930

Gene Official Name

CD19

Gene Alias

B4, CVID3

Protein Sub-location

Transmembrane Protein

Category

Therapeutics Target, Immuno-oncology Target, INN Index

Pre-made CD19-specific INN-index biosimilar (antibody&conjugates)-lisocabtagene maraleucel, obecabtagene autoleucel, Obexelimab, brexucabtagene autoleucel, zamtocabtagene autoleucel, tisagenlecleucel, axicabtagene ciloleucel, Coltuximab, Loncastuximab, taplitumomab paptox, Tafasitamab, azercabtagene zapreleucel, Blinatumomab, acmucabtagene autoleucel, evoncabtagene pazurgedleucel, Inebilizumab, Ensomafusp, relmacabtagene autoleucel, coltuximab ravtansine, loncastuximab tesirine, Denintuzumab, tebrocabtagene autoleucel, ensomafusp alfa, vadacabtagene leraleucel, denintuzumab mafodotin, Duvortuxizumab

Anti-CD19 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Filters Sort results
Reset Apply
Cat No.
Products Name (INN Index)
INN Name
Previous Name
Target
Format
Order
Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody
Blinatumomab
NA
CD19,CD3E
Bispecific T-Cell Engager
Pre-Made Coltuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
Coltuximab
NA
CD19
Whole mAb ADC
Pre-Made Denintuzumab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
Denintuzumab
NA
CD19
Whole mAb ADC
Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody
Duvortuxizumab
NA
CD19,CD3E
Bispecific scFv with Crossover
Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
Inebilizumab
NA
CD19
Whole mAb
Pre-Made Loncastuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
Loncastuximab
NA
CD19
Whole mAb ADC
Pre-Made Obexelimab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
Obexelimab
NA
CD19
Whole mAb
Pre-Made Tafasitamab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
Tafasitamab
NA
CD19
Whole mAb
Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3
Ensomafusp
NA
CD19
Fusion Protein
Pre-Made Taplitumomab Paptox biosimilar, Fusion Protein, Taplitumomab-Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody s
taplitumomab paptox
NA
CD19
Fusion Protein
Pre-Made Coltuximab Ravtansine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugate
coltuximab ravtansine
NA
CD19
Whole mAb ADC
Pre-Made Denintuzumab Mafodotin Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugate
denintuzumab mafodotin
NA
CD19
Whole mAb ADC
Pre-Made Ensomafusp Alfa Alfaiosimilar, Bispecific, Anti-Cd19; Tnfrsf9 Antibody: Anti-B4/CVID3;ILA/4-1BB/CDw137 therapeutic antibody
ensomafusp alfa
NA
CD19,TNFRSF9
Bispecific
Pre-Made Loncastuximab Tesirine Biosimilar, Whole Mab Adc, Anti-Cd19 Antibody: Anti-B4/CVID3 therapeutic antibody Drug Conjugate
loncastuximab tesirine
NA
CD19
Whole mAb ADC

Anti-CD19/ B4/ CVID3 antibody for FACS & in-vivo assay| GMab

Pre-made anti-CD19 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD19 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Filters Sort results
Reset Apply
Cat No.
Antibody Name
Format
Classified by tag
Order
Anti-CD19 monoclonal antibody
mab
FACS/Biofunctional Antibody, Therapeutics Target antibody